A B S T R A C T Chronic cimetidine therapy has been shown to suppress circulating concentrations of immunoreactive parathyroid hormone (iPTH) in hemodialysis patients. To evaluate the long-term metabolic effects of cimetidine treatment, we studied seven chronically uremic dogs for 20 wk. The dogs were studied under metabolic conditions before, during, and after cimetidine therapy. iPTH fell progressively in the five treated dogs from 536±70,leq/ml (mean±SE) (nl < 100 ,uleq/ml) before treatment to 291±25 ,leq/ml at 12 wk (P < 0.001) and 157±32 u.leq/ml at 20 wk (P < 0.001). The control dogs showed no consistent change in iPTH. The fall in iPTH was not associated with a change in serum ionized calcium. However, serum phosphorus decreased from 5.7±0.9 mg/dl to 3.4±0.2 mg/dl by the 20th wk (P < 0.05). By contrast, the serum concentration of 1,25-dihydroxycholecalciferol increased in all treated dogs from 33.4±4.3 pg0ml to 51.8±2.4 pg/ml during treatment (P < 0.01). Calcium balance was negative in all seven dogs before cimetidine (-347±84 mg/72 h) and remained so in the control dogs; it became positive in the five treated dogs after 12 wk (1,141±409 mg/72 h) (P < 0.05). Phosphorus balance, 24-h fractional phosphate excretion, and creatinine clearance remained unchanged. Pooled samples of serum obtained during the control and 20th wk of therapy were fractionated by gel filtration and the eluates assayed for immunoreactivity. The decrease in iPTH was associated with a decrease in all the immunoreactive species, indicating suppression of parathyroid gland secretion.
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These observations indicate that cimetidine suppressed circulating concentration ofbiologically active INTRODUCTION Secondary hyperparathyroidism is a serious complication of chronic renal failure and has been associated with many aspects of the uremic syndrome (1, 2) . For this reason, the prevention and treatment of uremic hyperparathyroidism (HPTH)l remains an area of active investigation (3) (4) (5) . We recently reported that cimetidine, a histamine H2 antagonist, decreased circulating concentrations of immunoreactive parathyroid hormone (iPTH) by 75% in a group of hemodialysis patients without associated changes in serum ionized calcium or phosphorus concentrations (6) . After discontinuation of the drug, hyperparathyroidism returned. This effect of cimetidine could be secondary to either a decrease in secretion of PTH or 
METHODS
Experimental design. Seven adult female mongrel dogs weighing 15-18 kg were studied. Renal insufficiency was induced by ligation of the majority of the branches of the renal artery on one side followed, 2 wk later, by contralateral nephrectomy (7) . After a period of stabilization varying from 12 to 18 mo, the dogs were studied under metabolic conditions described previously (8) . In brief, after a period of adjustment in metabolic cages, control observation was made for 1 wk. Five dogs then received cimetidine in tablet form for 20 wk; the tablets were placed in the pharynx and swallowing was assured by observation. Three dogs received 300 mg daily and two received 300 mg twice daily. Two dogs served as controls and did not receive cimetidine. All dogs remained in metabolic cages for four additional consecutive weeks during which the experimental observations were made. The dogs were then removed from the cages and placed in runs for 7 wk. The same amount of diet was offered daily. The dogs were then returned to cages for further balance studies on the 12th wk. Cimetidine treatment was then continued for a total of 20 wk. 14 wk after discontinuation of cimetidine the dogs were restudied in the balance cages.
The dogs ate Purina high-protein dog meal (Ralston Purina Co., St. Louis, Mo.) containing 1.6 g calcium, 0.950 g phosphorus, 0.150 g magnesium, and 176 U vitamin D/100 g diet. Analysis of the diet confirmed the labeled value for the diet's calcium, phosphorus, and magnesium content within 10%. 300 g of the diet were offered daily while the dogs were in the cages. The amount of diet actually consumed was determined by the difference of food available to the dogs and the amount remaining after each day. The partially exposed position of the feeding pan in the cage door prevented any scattering of the diet thereby insuring accurate measurements of intake. Blood samples were obtained anaerobically three times a week during balance studies at 10 a.m. from an anterior limb vein before changing the food. Samples were analyzed for ionized calcium, phosphorus, iPTH, and creatinine.
Blood samples were also obtained during the 20th wk of therapy and 7, 14, and [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 
Analytical methods
Formal 72-h metabolic balances were performed during the control, 1st, 2nd, 3rd, 4th, and 12th wk of treatment and 14 wk after discontinuation of treatment. 24-h urines were collected during the balance study and analyzed for calcium, phosphorus, and creatinine. Carmine red dye was given via orogastric tube on Mondays and Thursdays and all stool passed between the appearance of the marker was collected. The dye marker appeared from 24 to 48 h after administration.
Collection of all stools between markers insured an accurate fecal collection representative of the 72 h of food intake. Stool was prepared for analysis as described previously (8) .
Total calcium concentration was measured in all samples by atomic absorption (Perkin-Elmer Corp., Instrument Div., Norwalk., Conn, model 107). Phosphorus and creatinine were measured by AutoAnalyzer and ionized calcium was measured with a selective ion flow-through electrode (Orion Research Inc., Cambridge, Mass., model 5520). Serum iPTH was assayed by methods previously described in great detail (9) (10) (11) . Antiserum CH-71 at a dilution of 1:125,000 was used, which crossreacts with intact hormone as well as NH2-and COOH-terminal fragments. Each sample was assayed in duplicate at two widely differing concentrations. The coefficient of variation of replicate samples was 9%. PTH levels are reported in arbitrary units (microliter equivalents per milliliter) relating the potency of the test serum to that of a standard uremic HPTH standard.
Serum collected from the five cimetidine-treated dogs during the control week and 20th wk of therapy was pooled, concentrated, and chromatographed on a Bio-Gel P-10 column (Bio-Rad Laboratories, Richmond, Calif.) to separate the different immunoreactive molecular species of circulating PTH. These methods have been described previously in great detail (10) .
Plasma 25 
RESULTS
The values for ionized calcium, phosphorus and iPTH are presented in Table I . The creatinine clearance ranged from 5.5 to 16.1 ml/min. Fasting ionized calcium was within the range seen for normal dogs ingesting a similar diet in our laboratory (14) . Serum phosphorus ranged from 3.8 to 9.0 mg/dl.
All dogs were hyperparathyroid before treatment (Table I ). The mean iPTH value was 561+54 ,uleq/ml (normal, < 100 ,uleq/ml) for all seven dogs. HPTH is a consistent finding in chronically uremic dogs (4, 5, 8, 9, 14, 15) . After 1 wk of cimetidine administration, the iPTH values fell in all five treated dogs by 12±4
,uleq/ml (P < 0.05). The fall in iPTH after cimetidine was progressive and by the 20th wk of therapy iPTH had fallen to 155+30 ,uleq/ml (P < 0.01) (not shown in Table I. tion and the eluates assayed for immunoreactivity (Fig.  2) . It is evident that the decrease in iPTH was associated with a decrease in all the immunoreactive species. This indicates that the decrease in circulating iPTH during cimetidine therapy was secondary to less hormone secretion from the parathyroid glands rather than modifications in peripheral hormone metabolism.
Serum ionized calcium did not change throughout the study period (Fig. 3) Metabolic balance studies revealed that during cimetidine therapy calcium balance became positive (Table I) . During the control week, the five dogs were in a negative calcium balance of -367±120 mg/72 h. Negative calcium balance is a consistent feature in chronically uremic man (16) and dogs (8) and is due to fecal calcium losses. 3 and 4 wk after initiation of cimetidine therapy, the mean change in calcium balance was +550±259 and +674±334 mg/72 h (Fig.  4) . These changes reached borderline significance Table I. (0.05 < P < 0. 1). During the 12th wk of cimetidine, calcium balance was positive in all five dogs and increased by a mean of 1,509±518 mg/72 h (P < 0.05). This was due to an increase in net intestinal calcium absorption from -304±94 mg072 h during the control week to + 1,180±419 mg/72 h during week 12 (P <0.05). In contrast calcium balance was never positive in the two control dogs. There were no changes in phosphorus balance, creatinine clearance, and 24 h fractional phosphate excretion during the balance periods (Table I) . Changes in vitamin D metabolites may be related to alterations in calcium balance. Circulating concentrations of 25-hydroxycholecalciferol, 24,25-dihydroxycholecalciferol, and 1,25-dihydroxycholecalciferol were measured before and during cimetidine therapy. Serum 25(OH)D increased insignificantly from 31.2±7.6 nglml before therapy to 35.3±6.0 ng/ml after therapy. However, 1,25(OH)2D increased in all treated dogs by a mean of 55% from 33.4±4.3 pg/ml before therapy to 51.8±2.4 pg/ml after therapy (P < 0.01). 24,25(OH)2D decreased concomitantly from 2.4±0.3 ng/ml to 1.9±0.2 ng/ml (P < 0.05) (Fig. 5) .
Despite the decrease in iPTH, serum ionized calcium concentration could have been maintained if bone had increased its sensitivity to the remaining PTH. To examine this possibility, the calcemic response to exogenous PTH was examined in all seven dogs. The maximal increase in serum ionized calcium in the five treated dogs was 0.24±0.02 mg/dl. This blunted response was not different from that seen in the two control uremic dogs in this study and eight uremic dogs with hyperparathyroidism previously reported from this laboratory (5) (Fig. 6 ).
DISCUSSION
Cimetidine was effective in decreasing circulating iPTH by 75% in our dogs with a remnant kidney and chronic renal insufficiency. Reduction ofiPTH was evident despite the persistence of those factors that led to secondary hyperparathyroidism, i.e., a decrease in renal function and maintenance of a "normal" phos- Table I. 2.mr cimetidine-treated dogs is compared with the two cRntrol uremic dogs and an additional eight uremic and eight normal dogs described previously (5) . The numbers at each point correspond to the dogs in Table I. phate intake. Elevated concentrations of circulating iPTH have been previously demonstrated in chronically uremic man and dog (4, 5, 8, 9, 15, 17, 18) . This elevation reflects both an increased rate of secretion of PTH and an accumulation ofmetabolites due to delayed excretion (19) . Intact PTH is metabolized by the liver and kidney to lower molecular weight fragments that are excreted primarily by glomerular filtration (1, 20) . In chronic renal disease, these metabolites accumulate and contribute to the elevation in serum iPTH. PTH immunoassays that measure COOH-fragments are particularly sensitive to changes in peripheral metabolism (19) . The decrease in iPTH during cimetidine therapy therefore could reflect either a change in secretory rate of hormone or an acceleration of peripheral metabolism. A comparison of the profile of immunoreactivity obtained after gel chromatography shows clearly that cimetidine did not affect the metabolism of PTH. Hence, cimetidine must have reduced the secretion of PTH by the parathyroids (10). An equally enhanced clearance of all species of iPTH by cimetidine is unlikely, as this would require an effect on liver, kidney, and bone, the organs involved in PTH metabolism.
Preliminary studies with parathyroid slices from normal bovine glands (21) and isolated dispersed cells from human adenomatous glands (22) have shown that histamine stimulates cAMP production and PTH release. These effects are blocked by cimetidine. Circulating iPTH in normal subjects acutely decreases with cimetidine infusion and returns to control levels when the infusion is terminated (21) . Histamine may therefore play a role in normal parathyroid physiology and hyperparathyroid conditions. Stimulation of PTH secretion by hypocalcemia and ,-agonists is felt to be secondary to activation of adenylate cyclase (23, 24) . It is possible that the parathyroid gland adenylate cyclase may be histamine sensitive, a characteristic of cardiac (25) and gastric adenylate cyclase (26) .
After withdrawal of cimetidine, iPTH values slowly increased, and only 20-30 wk later did iPTH return to pretreatm-ient levels. Accumulation of cimetidine and its metabolites in chronic uremia may accounit for the delayed return of iPTH values after withdrawal. A single oral dose of cimetidine is excreted in the urine mostly unchanged and as a sulfoxide. However, substantial amounts of poorly characterized polar conjugates are also detected (27) . Cimetidine excretion is depressed in renal failure (28) (8, 16, (30) (31) (32) . Our dogs with creatinine clearances -15% of normal were not severely uremic but were in negative calcium balance despite a calcium intake of >3 g daily. This defect has been attributed to a deficiency of 1,25(OH)2D. Although the normal range of circulating 1,25(OH)2D levels in dogs offered a similar diet is unknown, our dogs were certainly not deficient in this metabolite as the mean concentration before cimetidine therapy was 33.4 pg/ml, a value within the normal range for man. Cimetidine increased circulating levels of 1,25(OH)2D in all five dogs. This was associated with a concomitant fall in the concentration of 24,25(OH)2D. The control of la-hydroxylation by PTH (33) , calcium (34) and phosphorus (35) has been described in various species. However, there are no data concerning modulation of metabolism of vitamin D by these factors in renal disease. The changes in D metabolites may have been secondary to the decrease in serum phosphate concenitration, an important modulator of renal la-and 24-hydroxylase activities (35) . Our studies suggest that 1,25(OH)2D levels will increase in dogs with renal insufficiency in response to a decrease in serum phosphorus. The increase in 1,25(OH)2D concentration probably accounts for the net positive calcium balance during cimetidine therapy. A possible role for phosphorus in peripheral 1,25(OH)2D metabolism has been postulated (36) and it is possible that metabolic degradation of 1,25(OH)2D was inhibited by the decrease in serum phosphorus. A direct suppressive effect of 1,25(OH)2D on PTH glandular secretion has been observed by some investigators (37) . It is possible that cimetidine directly stimuilated renal synthesis of 1,25(OH)2D thereby decreasing iPTH. However, the decrease in iPTH occurred much earlier than the changes in calcium balance, suggesting that the vitamin D effect was a later and therefore secondary event.
The mechanisms responsible for the dec rease in serum phosphorus conicentration are unclear. Despite the increase in net gastrointestinal calciuIml absorption with cimetidine, phosphorus absorption remiiained unchanged. Coburn et al. (38) have shown that the administration of 1,25(OH)2D to chronically uremic patients will enhance net intestinal absorption of calciumn and phosphorus to an equivalent degree. Ifthe increase in 1,25(OH)2D concentration in our dogs is responsible for the changes in calciumi balance, similar effects on phosphorus balance should have been observed. Nonietheless, the balance data clearly exclude decreased intestinal absor-ption or increase renal losses as contributing to the change in serumii phosphorus. After 3 wk of cimetidine treatment, serunm phosphorus had decreased significantly but net gastrointestinal absorption and urinary excretion of phosphorrus varied inconsistently from the conttrol week. These observations exclude primary chaniges in phosphorus balance as operative and evoke shifts of phosphorus within body comiipartments as a tenable explanation. The decreased concentration of iPTH after cimetidine may have caused less phosphorus to be lost from bone, thereby decreasing serum phosphorus. Alternatively, intracellular accunmuilation of phosphorus secondary to changes in vitamin D metabolites (39) or incorporation into phospholipids (40) may be responsible. The relative contribution of any of these possibilities is unknown. Despite the decrease in the serum and filtered load of phosphorus, renal phosphorus excretion was unchanged. This relative phosphaturia mlay have been secondary to the increase in 1,25(OH)2D, as this agent will cause phosphaturia when administered chronically to thyroparathyroidectomized rats (41) .
More than a decade ago, secondary HPTH was postulated to be directed at the maintenance of phosphate homeostasis in chronic uiremia (15) . Each decrement in gomertilar filtration rate wouild be associated with transient hyperphosphatemia, hypocalcemia, and anl increase in PTH secretion. Secondary HPTH would cauise phosphaturia and restore phosphate balance thereby normalizing serum phosphate and calcium levels. As renal fuinction deteriorates, phosphate balance would be mainitained at the expense of increasingly severe HPTH. Although Swenson et al. (42) have shown that phosphate homeostasis may be maintained in parathyroidectomized uremic dogs given vitamin D, a direct effect of vitamin D on renal phosphate handling in uremia was not excluded. Our data indicate that atteniuation of HPTH does not impair phosphate homeostasis in uremic dogs. Although PTH is critical for phosphate homeostasis in chronic renal disease, our observations suggest that factors other than hyperparathyroidism may also be involved.
